Navigation Links
Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors

ANN ARBOR, Mich., July 18 /PRNewswire/ -- Velcura Therapeutics, Inc. CEO Michael Long, Ph.D., announced that William F. Brinkerhoff has joined the Board of Directors of the biotechnology company, which completed a first-in-man clinical trial for VEL-0230, a powerful anti-inflammatory agent stimulating bone formation and inhibiting bone loss. Velcura is investigating its lead compound as a treatment for rheumatoid arthritis and other bone diseases.

Bill Brinkerhoff is the chief operating officer of Cerenis Therapeutics, which is focused on the discovery, development and commercialization of breakthrough HDL-related therapies for the treatment of cardiovascular and metabolic diseases.

"In joining Velcura's Board, I look forward to assisting them in their mission of developing therapies that restore bone health," said Bill Brinkerhoff.

Before founding Cerenis in 2005, Brinkerhoff was vice president of business development for Esperion Therapeutics in Ann Arbor, where he successfully negotiated multiple large potential partnering agreements prior to Esperion's acquisition by Pfizer. Before joining Esperion in 2002, he was the director of business development and director of market planning and sales operations, for Sankyo Parke Davis in Parsippany, New Jersey.

A graduate of the University of Michigan, Brinkerhoff earned his Master of Business Administration with Distinction in 1989. He also has bachelor's and master's degrees in Industrial Engineering and Operations Research from U-M's College of Engineering.

Velcura's other directors are Michael W. Long and Bill Orobone, CEO of Syneptics, an alternative energy financing entity.

About Velcura Therapeutics, Inc.

Velcura Therapeutics, Inc. is an early stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to understand human bone disease and to discover novel therapeutics that restore bone health. Velcura develops highly differentiated therapies for bone disease; specifically, therapies that restore the balance between bone building and bone loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize these compounds. More information is at .
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Michael W. Long, Ph.D.

SOURCE Velcura Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
2. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
3. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
4. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
5. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
6. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
7. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
8. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
11. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... , November 26, 2015 ... --> adds "Global Repaglinide ... "Investigation Report on China Repaglinide Market, ... forecasts data and information to its ... . --> ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer ... incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product ... Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not only ...
(Date:11/26/2015)... ... 2015 , ... Inevitably when people think Thanksgiving, they also think Holiday sales ... Black Friday and Cyber Monday massage chair sales to receive the best ... low to find the best massage chair deals, they can see all of the ...
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan ... a franchise owner, Somu now offers travelers, value and care based Travel Services, ... cruise sales, as well as, cabin upgrades and special amenities such as, shore ...
(Date:11/26/2015)... , ... November 26, 2015 , ... Jobs in hospital ... healthcare professionals and offered by healthcare staffing agency Aureus Medical Group . ... month of October 2015 among those searching for healthcare jobs through the company’s website, ...
(Date:11/26/2015)... BOSTON, Mass. (PRWEB) , ... November 26, 2015 ... ... a thorough second medical opinion process, participated in the 61st annual Employee Benefits ... Benefit Plans and took place Sunday, November 8th through Wednesday, November 11th, 2015. ...
Breaking Medicine News(10 mins):